Childhood vaccination schedule: Difference between revisions
Jump to navigation
Jump to search
| Line 63: | Line 63: | ||
|style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | |style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | ||
| colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |4th dose | | colspan="2" align="center" style="background: #F0E68C; padding: 5px text-align:center" |4th dose | ||
| colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|style="background: #F0E68C; padding: 5px text-align:center" |5th dose | |style="background: #F0E68C; padding: 5px text-align:center" |5th dose | ||
| Line 82: | Line 82: | ||
See footnote 4 | See footnote 4 | ||
| colspan="4" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="4" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
| colspan="5" style="background: # | | colspan="5" style="background: #DCDCDC; padding: 5px text-align:center" | | ||
|- | |- | ||
|align="center" style="background:#DCDCDC;"|Pneumococcal conjugate5 (PCV13) | |align="center" style="background:#DCDCDC;"|Pneumococcal conjugate5 (PCV13) | ||
| Line 91: | Line 91: | ||
|style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | |style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | ||
|style="background: #AFEEEE; padding: 5px text-align:center" | | |style="background: #AFEEEE; padding: 5px text-align:center" | | ||
| colspan="2" style="background: #F0E68C; padding: 5px text-align:center" |4th dose | | colspan="2" align="center" style="background: #F0E68C; padding: 5px text-align:center" |4th dose | ||
| colspan="4" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="4" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
| colspan="5" style="background: # | | colspan="5" style="background: #DCDCDC; padding: 5px text-align:center" | | ||
|- | |- | ||
|align="center" style="background:#DCDCDC;"|Inactivated poliovirus6 (IPV: <18 yrs) | |align="center" style="background:#DCDCDC;"|Inactivated poliovirus6 (IPV: <18 yrs) | ||
| Line 100: | Line 100: | ||
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose | |style="background: #F0E68C; padding: 5px text-align:center" |1st dose | ||
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose | |style="background: #F0E68C; padding: 5px text-align:center" |2nd dose | ||
| colspan="5" style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | | colspan="5" align="center" style="background: #F0E68C; padding: 5px text-align:center" |3rd dose | ||
| colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="2" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|style="background: #F0E68C; padding: 5px text-align:center" |4th dose | |style="background: #F0E68C; padding: 5px text-align:center" |4th dose | ||
| Line 156: | Line 156: | ||
|style="background:#F8F8FF; | | |style="background:#F8F8FF; | | ||
|style="background:#F8F8FF; | | |style="background:#F8F8FF; | | ||
| colspan="11" style="background: # | | colspan="11" align="center" style="background: #DCDCDC; padding: 5px text-align:center" |See footnote 11 | ||
|style="background: #F0E68C; padding: 5px text-align:center" |1st dose | |style="background: #F0E68C; padding: 5px text-align:center" |1st dose | ||
|style="background: #AFEEEE; padding: 5px text-align:center" | | |style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|style="background: #F0E68C; padding: 5px text-align:center" |2nd dose | |align="center" style="background: #F0E68C; padding: 5px text-align:center" |2nd dose | ||
|style="background: #AFEEEE; padding: 5px text-align:center" | | |style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|- | |- | ||
| Line 193: | Line 193: | ||
|style="background:#F8F8FF; | | |style="background:#F8F8FF; | | ||
|colspan="3" style="background: #AFEEEE; padding: 5px text-align:center" | | |colspan="3" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|style="background:#F0E68C; |See footnote 13 | |style="background:#F0E68C; text-align:center" |See footnote 13 | ||
| colspan="3" colspan="3" style="background: #AFEEEE; padding: 5px text-align:center" | | | colspan="3" colspan="3" style="background: #AFEEEE; padding: 5px text-align:center" | | ||
|- | |- | ||
Revision as of 18:57, 11 April 2017
Template:Vaccination schedule Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Childhood vaccination schedule
The following table summarizes the vaccination schedule for Adolescents Aged 18 Years or Younger based on CDC 2017 recommendation.
| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19-23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13-15 yrs | 16 yrs | 17-18 yrs | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hepatitis B1 (HepB) | 1st dose | 2nd dose | 3rd dose | ||||||||||||||||
| Rotavirus2 (RV) RV1 (2-dose series);
RV5 (3-dose series) |
1st dose | 2nd dose | See footnote 2 | ||||||||||||||||
| Diphtheria, tetanus, & acellular pertussis3
(DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | 4th dose | 5th dose | ||||||||||||||
| Haemophilus influenzae type b4 (Hib) | 1st dose | 2nd dose | See footnote 4 | 3rd or 4th dose,
See footnote 4 |
|||||||||||||||
| Pneumococcal conjugate5 (PCV13) | 1st dose | 2nd dose | 3rd dose | 4th dose | |||||||||||||||
| Inactivated poliovirus6 (IPV: <18 yrs) | 1st dose | 2nd dose | 3rd dose | 4th dose | |||||||||||||||
| Influenza7 (IIV) | Annual vaccination (IIV) 1 or 2 doses | Annual vaccination (IIV) 1 dose only | |||||||||||||||||
| Measles, mumps, rubella8 (MMR) | See footnote 8 | 1st dose | 2nd dose | ||||||||||||||||
| Varicella9 (VAR) | 1st dose | 2nd dose | |||||||||||||||||
| Hepatitis A1 0 (HepA) | 2-dose series, See footnote 10 | ||||||||||||||||||
| Meningococcal1 1 (Hib-MenCY >6 weeks;
MenACWY-D >9 mos; MenACWY-CRM ≥2 mos) |
See footnote 11 | 1st dose | 2nd dose | ||||||||||||||||
| Tetanus, diphtheria, & acellular pertussis12 (Tdap: >7 yrs) | Tdap | ||||||||||||||||||
| Human papillomavirus1 3 (HPV) | See footnote 13 | ||||||||||||||||||
| Meningococcal B1 1 | |||||||||||||||||||
| Pneumococcal polysaccharide5 (PPSV23) | |||||||||||||||||||
See also
Sources and notes
External links
- National Center for Immunization and Respiratory Diseases. "CDC National Immunization Program". CDC. Retrieved 2006-09-18.
- "MMR vaccine and the autism epidemic: In a compulsory inoculation program, it is the responsibility of the developers, promoters and enforcers to prove safety and efficacy". MMR vaccine and the autism epidemic. InformedChoice.info. Retrieved 2006-09-18.
- National Health Service of UK. "UK Immunisation Schedule and Information". NHS. Retrieved 2006-11-03.
de:Impfkalender id:Jadwal imunisasi